GlassScriptPhysician profile
Ranjana Verma
NPI 1144243783
$3,342.85
in general payments reported to CMS, 2019-2025
22 companies · $670 in 2025
The $670 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $87.54 · 2021: $578 · 2022: $381 · 2023: $423 · 2024: $656 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $436.54 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $435.03 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $385.21 | 2021-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.71 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $307.92 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $265.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $151.92 | 2022-2024 | Azstarys |
| Lundbeck LLC | $137.79 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $125.41 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $116.61 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $106.32 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $96.34 | 2021-2024 | Ingrezza |
| Tris Pharma INC | $88.92 | 2019-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $88.30 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $85.86 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $38.71 | 2019 | |
| Allergan, INC. | $32.17 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.74 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $14.87 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $14.84 | 2021 | |
| Shire North American Group INC | $12.28 | 2019 | |
| Tms Neurohealth Centers INC. | $9.49 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjana Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.